151 related articles for article (PubMed ID: 34785505)
41. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
42. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
Satoh M; Iwabuchi K
Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
[TBL] [Abstract][Full Text] [Related]
43. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
44. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity.
Lombardi V; Stock P; Singh AK; Kerzerho J; Yang W; Sullivan BA; Li X; Shiratsuchi T; Hnatiuk NE; Howell AR; Yu KO; Porcelli SA; Tsuji M; Kronenberg M; Wilson SB; Akbari O
J Immunol; 2010 Feb; 184(4):2107-15. PubMed ID: 20083656
[TBL] [Abstract][Full Text] [Related]
45. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
Nowak M; Arredouani MS; Tun-Kyi A; Schmidt-Wolf I; Sanda MG; Balk SP; Exley MA
PLoS One; 2010 Jun; 5(6):e11311. PubMed ID: 20593019
[TBL] [Abstract][Full Text] [Related]
46. Poly(I:C) promotes the production of IL-17A by murine CD1d-driven invariant NKT cells in airway inflammation.
Vultaggio A; Nencini F; Pratesi S; Petroni G; Romagnani S; Maggi E
Allergy; 2012 Oct; 67(10):1223-32. PubMed ID: 22882449
[TBL] [Abstract][Full Text] [Related]
47. Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.
Choi J; Rudak PT; Lesage S; Haeryfar SMM
J Immunol; 2019 Oct; 203(7):1808-1819. PubMed ID: 31462506
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
[TBL] [Abstract][Full Text] [Related]
49. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
50. Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors.
Li YR; Zhou Y; Wilson M; Kramer A; Hon R; Zhu Y; Fang Y; Yang L
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886891
[TBL] [Abstract][Full Text] [Related]
51. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
[TBL] [Abstract][Full Text] [Related]
52. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
53. Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation.
Emoto M; Yoshida T; Fukuda T; Kawamura I; Mitsuyama M; Kita E; Hurwitz R; Kaufmann SH; Emoto Y
Infect Immun; 2010 Jun; 78(6):2667-76. PubMed ID: 20351146
[TBL] [Abstract][Full Text] [Related]
54. Miscarriage induced by adoptive transfer of dendritic cells and invariant natural killer T cells into mice.
Negishi Y; Ichikawa T; Takeshita T; Takahashi H
Eur J Immunol; 2018 Jun; 48(6):937-949. PubMed ID: 29520760
[TBL] [Abstract][Full Text] [Related]
55. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Yang G; Artiaga BL; Lewis ST; Driver JP
Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
[TBL] [Abstract][Full Text] [Related]
56. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
57. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
[TBL] [Abstract][Full Text] [Related]
58. Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-γ.
Sakurai T; Inamine A; Iinuma T; Funakoshi U; Yonekura S; Sakurai D; Hanazawa T; Nakayama T; Ishii Y; Okamoto Y
Clin Exp Immunol; 2014 Oct; 178(1):65-74. PubMed ID: 24943738
[TBL] [Abstract][Full Text] [Related]
59. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
60. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
